Authors:
Namer, M
Soler-Michel, P
Turpin, F
Chinet-Charrot, P
de Gislain, C
Pouillart, P
Delozier, T
Luporsi, E
Etienne, PL
Schraub, S
Eymard, JC
Serin, D
Ganem, G
Calais, G
Maillart, P
Colin, P
Trillet-Lenoir, V
Prevost, G
Tigaud, D
Clavere, P
Marti, P
Romieu, C
Wendling, JL
Citation: M. Namer et al., Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer, EUR J CANC, 37(9), 2001, pp. 1132-1140
Authors:
Freyer, G
Ligneau, B
Schlumberger, M
Blandy, C
Contedevolx, B
Trillet-Lenoir, V
Lenoir, GM
Chau, N
Dazord, A
Citation: G. Freyer et al., Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: Trends for future evaluations, ANN ONCOL, 12(10), 2001, pp. 1461-1465
Authors:
Freyer, G
Bossard, N
Romestaing, P
Mornex, F
Chapet, O
Trillet-Lenoir, V
Gerard, JP
Citation: G. Freyer et al., Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 Phase I trial, J CL ONCOL, 19(9), 2001, pp. 2433-2438
Authors:
Trillet-Lenoir, V
Lotz, JP
Le Cesne, A
Roy, P
Edouard, A
Citation: V. Trillet-lenoir et al., Reflexions from the experience of the French CLEOPATRE program and concerns about the status of clinical research on small cell lung cancer, LUNG CANC, 33(2-3), 2001, pp. 303-307
Authors:
Freyer, G
Ligneau, B
Tranchand, B
Ardiet, C
Souquet, PJ
Court-Fortune, I
Riou, R
Rebattu, P
Morignat, E
Boissel, JP
Trillet-Lenoir, V
Girard, P
Citation: G. Freyer et al., The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT), LUNG CANC, 31(2-3), 2001, pp. 247-256
Authors:
Bennouna, J
Monnier, A
Riviere, A
Milleron, B
Lemarie, E
Trillet-Lenoir, V
Soussan-Lazard, K
Berille, J
Douillard, JY
Citation: J. Bennouna et al., A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer, EUR J CANC, 36(9), 2000, pp. 1107-1112
Authors:
Dumortier, J
Freyer, G
Sasco, AJ
Frappart, L
Zenone, T
Romestaing, P
Trillet-Lenoir, V
Citation: J. Dumortier et al., Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: Report on a new case and review of the literature, ANN ONCOL, 11(3), 2000, pp. 355-358
Authors:
Freyer, G
Tranchand, B
Ligneau, B
Ardiet, C
Souquet, PJ
Court-Fortune, I
Riou, R
Rebattu, P
Boissel, JP
Trillet-Lenoir, V
Girard, P
Citation: G. Freyer et al., Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study, BR J CL PH, 50(4), 2000, pp. 315-324
Authors:
Voog, E
Merrouche, Y
Trillet-Lenoir, V
Lasset, C
Peaud, PY
Rebattu, P
Negrier, S
Citation: E. Voog et al., Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary, AM J CL ONC, 23(6), 2000, pp. 614-616
Authors:
Freyer, G
Rougier, P
Bugat, R
Droz, JP
Marty, M
Bleiberg, H
Mignard, D
Awad, L
Herait, P
Culine, S
Trillet-Lenoir, V
Citation: G. Freyer et al., Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure, BR J CANC, 83(4), 2000, pp. 431-437
Authors:
Cottin, V
Arpin, D
Lasset, C
Cordier, JF
Brune, J
Chauvin, F
Trillet-Lenoir, V
Citation: V. Cottin et al., Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole, ANN ONCOL, 10(7), 1999, pp. 809-815
Authors:
Freyer, G
Dazord, A
Schlumberger, M
Conte-Devolx, B
Ligneau, B
Trillet-Lenoir, V
Lenoir, GM
Citation: G. Freyer et al., Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: A multicentric pilot-evaluation, ANN ONCOL, 10(1), 1999, pp. 87-95
Authors:
Nabholtz, JM
Senn, HJ
Bezwoda, WR
Melnychuk, D
Deschenes, L
Douma, J
Vandenberg, TA
Rapoport, B
Rosso, R
Trillet-Lenoir, V
Drbal, J
Molino, A
Nortier, JWR
Richel, DJ
Nagykalnai, T
Siedlecki, P
Wilking, N
Genot, JY
Hupperets, PSGJ
Pannuti, F
Skarlos, D
Tomiak, EM
Murawsky, M
Alakl, M
Riva, A
Aapro, M
Citation: Jm. Nabholtz et al., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy, J CL ONCOL, 17(5), 1999, pp. 1413-1424
Authors:
Tranchand, B
Amsellem, C
Chatelut, E
Freyer, G
Iliadis, A
Ligneau, B
Trillet-Lenoir, V
Canal, P
Lochon, I
Ardiet, CJ
Citation: B. Tranchand et al., A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients, CANC CHEMOT, 43(4), 1999, pp. 316-322
Authors:
Wang, Q
Lasset, C
Desseigne, F
Saurin, JC
Maugard, C
Navarro, C
Ruano, E
Descos, L
Trillet-Lenoir, V
Bosset, JF
Puisieux, A
Citation: Q. Wang et al., Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer, HUM GENET, 105(1-2), 1999, pp. 79-85
Authors:
Kurtz, JE
Trillet-Lenoir, V
Bugat, R
Negrier, S
Adenis, A
Kayitalire, L
Ripoche, V
Dufour, P
Citation: Je. Kurtz et al., Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study, B CANCER, 86(2), 1999, pp. 202-206